SYD-4228 by Byondis for Follicular Lymphoma: Likelihood of Approval

SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma.

First Opinion readers on Hatch-Waxman, new-patient visit times, mpox, and more

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers,

October 5, 2024

AI-driven data analysis could exacerbate misaligned incentives in biomedical research

This summer OpenAI released Code Interpreter, a plug-in for the popular ChatGPT tool that allows it to take in datasets, write and run Python code,

September 29, 2023

Chime looks to expand manufacturing capacity and establish European presence

China-headquartered Chime Biologics has announced plans to expand its manufacturing and product offerings. Image Credit: Corona Borealis Studio / Shutterstock. Chime Biologics has unveiled plans

August 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.